{"id":"W2560280991","doi":"10.1089/dia.2016.0261","title":"Glucose Exposure and Variability with Empagliflozin as Adjunct to Insulin in Patients with Type 1 Diabetes: Continuous Glucose Monitoring Data from a 4-Week, Randomized, Placebo-Controlled Trial (EASE-1)","year":2016,"lang":"en","type":"article","venue":"Diabetes Technology & Therapeutics","topic":"Diabetes Management and Research","field":"Medicine","cited_by":53,"is_retracted":false,"has_abstract":true,"ca_institutions":"Boehringer Ingelheim (Canada)","funders":"Eli Lilly and Company","keywords":"Empagliflozin; Medicine; Placebo; Insulin; Diabetes mellitus; Interquartile range; Internal medicine; Type 2 diabetes; Endocrinology; Hypoglycemia; Type 1 diabetes","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003943557,0.001041101,0.002884616,0.0003652269,0.0002753573,0.0009450314,0.0007456442,0.001091478,0.003441398],"category_scores_gemma":[0.003845328,0.0004389939,0.002418333,0.0005683394,0.000648801,0.0007141468,0.0004200742,0.001854358,0.0002520963],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004861497,"about_ca_system_score_gemma":0.0006735531,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004360905,"about_ca_topic_score_gemma":0.000834302,"domain_scores_codex":[0.9983467,0.0009723043,0.0001753574,0.0002506982,0.0001587078,0.00009626694],"domain_scores_gemma":[0.9969043,0.001116632,0.001148756,0.0002515428,0.000160531,0.0004182218],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9705774,0.004056735,0.005208142,0.0006486167,0.002212645,0.00002391708,0.00002658801,0.0002658477,0.001679368,0.00002240293,0.0002829449,0.01499532],"study_design_scores_gemma":[0.8670285,0.09193869,0.03584155,0.00007550795,0.00308914,0.00007057413,0.0000179837,0.0006828863,0.0006926549,0.00005805048,0.0004725319,0.00003195742],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9914056,0.005895484,0.0004684415,0.0002445613,0.0001450281,0.000637749,0.0005878898,0.00004010563,0.0005751815],"genre_scores_gemma":[0.9937273,0.002035236,0.001232278,0.000373134,0.000382844,0.0009029813,0.0008804384,0.00001000846,0.0004556877],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003943557,"threshold_uncertainty_score":0.02085578,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01842688632414799,"score_gpt":0.2678732901847652,"score_spread":0.2494464038606173,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}